ArticleAmerican journal of cancer research2025
Reduced EZH1/2 expression in imipridone-treated cells correlates with synergy following combinations with EZH1/2 or HDAC inhibitors in diffuse glioma and other tumors.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- ONC201/dordaviprone for H3 K27M-mutant tumors: Discovery, mechanisms, therapeutic potential, and future directions.Genes & diseases · 2027Review
- Dysregulation of human ClpP using small molecules with piperazine-based scaffold for diffuse intrinsic pontine glioma therapy validated by patient-derived tumor organoids.Research square · 2026Article
- Targeting the Mitochondria in High-Grade Gliomas.Cancers · 2025Review
- Combination of the First-in-Class Imipridone ONC201 and Standard Anticancer Therapies as a Rational Approach for Therapeutic Benefit.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Small molecule imipridones including ONC201, ONC206 and ONC212 have anti-cancer activity mediated in part through the integrated stress response, induction of TRAIL and its receptor DR5, and activation of mitochondrial caseinolytic protease ClpP with impaired oxidative phosphorylation. ONC201 provides clinical benefit in a subset of patients with histone H3K27M-mutated diffuse glioma (DG). We hypothesized that EZH2 inhibitors (EZH2i) may sensitize tumors to imipridones by mimicking H3K27M mutation. EZH1 is a homolog and alternative for EZH2 in assembling PRC2 complex. We combined ONC201, ONC206 or ONC212 plus dual EZH1/2i in tumors and observed synergy. We observed synergies with imipridones combined with HDACi or triple combination of ONC201/ONC206, EZH2i and HDACi in DG, GBM, prostate cancer and SCLC cells. Our observations implicate EZH1/2 suppression in mechanism of anti-cancer effect of imipridones. We investigated effects of imipridones on EZH1/2 in DG cells and solid tumor cells including GBM, CRC, PDAC, SCLC, prostate cancer, gastric cancer, HCC and breast cancer cells and found inhibition of EZH1/EZH2 expression across tumor types and cell viability suppression by imipridones is correlated with EZH1/2 reduction. Imipridone or EZH2i-treated tumor cells showed similar cytokine profile changes. RNA-seq showed ONC201 and EHZ2i tazemetostat-treated cells have similar transcriptional profiles and share overlap of top regulated genes. Thus, imipridones inhibit EZH1/2 in tumor cells in a manner that mimics H3K27M mutation supporting their role in anti-cancer efficacy. ONC201 and EZH2i share similar targets and actions on tumors. Synergistic combinations of imipridones plus EZH1/2i or imipridones, EZH2i and HDACi merit further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.